{"id":"NCT02364999","sponsor":"Pfizer","briefTitle":"A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC","officialTitle":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04","primaryCompletion":"2017-05","completion":"2017-12","firstPosted":"2015-02-18","resultsPosted":"2018-06-27","lastUpdate":"2019-02-07"},"enrollment":719,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Bevacizumab-Pfizer","otherNames":[]},{"type":"DRUG","name":"Bevacizumab-EU","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]}],"arms":[{"label":"Bevacizumab-Pfizer","type":"EXPERIMENTAL"},{"label":"Bevacizumab-EU","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC.","primaryOutcome":{"measure":"Objective Response Rate (ORR) by Week 19","timeFrame":"25 weeks","effectByArm":[{"arm":"PF-06439535","deltaMin":45.3,"sd":null},{"arm":"Bevacizumab-EU","deltaMin":44.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":263,"countries":["United States","Australia","Brazil","Bulgaria","Chile","Croatia","Czechia","France","Germany","Greece","Hungary","India","Italy","Japan","Malaysia","Netherlands","Philippines","Poland","Romania","Russia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["31768697","31338773"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7391003&StudyName=A%20Phase%203%20Randomized%2C%20Double-blind%20Study%20Of%20Pf%2006439535%20Plus%20Paclitaxel-carboplatin%20And%20Bevacizumab%20Plus%20Paclitaxel%20-carboplatin%20For%20The%20First-line%20Treatment%20Of%20Patients%20With%20Advanced%20Non-squamous%20Non-small%20Cell%20Lung%20Cancer."]},"adverseEventsSummary":{"seriousAny":{"events":81,"n":356},"commonTop":["Alopecia","Anaemia","Fatigue","Nausea","Neutropenia"]}}